Decreasing HIV Drug Resistance in the United Kingdom

September 2007
Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, pvi
Academic Journal
The article discusses the study "A decreasing prevalence of antiretroviral drug resistance in the UK: evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom." In the study, the researchers conducted analysis of major resistance mutations to determine time-dependent changes in antiretroviral resistance. From the data gathered, the researchers found out a nationwide decrease in antiretroviral resistance. They stressed that such decrease may be the result of the availability of more effective therapy to HIV-positive persons.


Related Articles

  • Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough. Baraboutis, Ioannis G.; Papastamopoulos, Vassilios; Georgiou, Ourania; Skoutelis, Athanasios T. // International Journal of STD & AIDS;Oct2007, Vol. 18 Issue 10, p722 

    We present a patient with chronic HIV-1 infection and primary multi-drug resistance, the magnitude of which was underestimated by the baseline genotypic resistance testing (GRT) due to reversion of some of the mutations of the transmitted strain. This resulted in complete failure of his first...

  • Long-term maraviroc use as salvage therapy in HIV-2 infection. Caixas, Umbelina; Ferreira, Joana; Marinho, Aline T.; Faustino, Inês; Grilo, Nádia M.; Lampreia, Fátima; Germano, Isabel; Monteiro, Emília C.; Pereira, Sofia A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2012, Vol. 67 Issue 10, p2538 

    The article discusses the case of a patient diagnosed with human immunodeficiency virus (HIV)-2. Information on the patient's combined antiretroviral therapy (cART) is provided. Atazanavir/ritonavir served as substitutes to lopinavir/ritonavir due to the patient's intolerance and poor adherence...

  • Raltegravir: The First HIV Type 1 Integrase Inhibitor. Hicks, Charles; Gulick, Roy M. // Clinical Infectious Diseases;4/1/2009, Vol. 48 Issue 7, p931 

    Raltegravir is the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor; it targets the strand transfer step of HIV-1 integration. Clinical trials have demonstrated that raltegravir-containing regimens have potent antiretroviral activity and are well tolerated in...

  • Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen. Hatano, Hiroyu; Hunt, Peter; Weidler, Jodi; Coakley, Eoin; Hoh, Rebecca; Liegler, Teri; Martin, Jeffrey N.; Deeks, Steven G. // Clinical Infectious Diseases;11/15/2006, Vol. 43 Issue 10, p1329 

    Background. Many treatment-experienced, HIV-infected patients who have limited therapeutic options for complete viral suppression continue to receive a partially suppressive treatment regimen pending the availability of at least 2 new antiretroviral drugs. The major risk of this approach is...

  • Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatment-naive patients. Hofstra, L. Marije; Nijhuis, Monique; Pingen, Marieke; Mudrikova, Tania; Riezebos-Brilman, Annelies; Simoons-Smit, Alberdina M.; Van Ham, Petra M.; Bierman, Wouter F. W.; Wensing, Annemarie M. J. // Journal of Antimicrobial Chemotherapy (JAC);Jun2013, Vol. 68 Issue 6, p1246 

    Background Transmitted resistant HIV may revert to wild-type in the absence of drug pressure due to reduced replication capacity (RC). We observed eight therapy-naive patients infected with HIV harbouring four mutations at nucleoside reverse transcriptase inhibitor (NRTI) resistance-related...

  • HIV Resistance Testing. Deresinski, Stan // Clinical Infectious Diseases;3/15/2005, Vol. 40 Issue 6, preceding p1 

    The article presents information on HIV resistance testing. The most recent guidelines for antiretroviral therapy for HIV- 1-infected adults and adolescents, published on October 29, 2004, recommend the use of HIV drug resistance testing in 3 circumstances: virologic failure during combination...

  • Prevalence of Drug-Resistant and Nonsubtype B HIV Strains in Antiretroviral-Naïve, HIV-Infected Individuals in New York State. Parker, Monica M.; Gordon, Daniel; Reilly, Andrew; Horowitz, Harold W.; Waters, Mark; Bennett, Ryan; Hallack, Renee; Smith, Joseph; Lamson, Daryl; Aydemir, Aida; Dvali, Natia; Agins, Bruce D.; Drusano, George L.; Taylor, Jill // AIDS Patient Care & STDs;Sep2007, Vol. 21 Issue 9, p644 

    The duration of HIV infection is usually unknown for most patients entering into HIV care. Data on the frequency at which resistance mutations are detected in these patients are needed to support practical guidance on the use of resistance testing in this clinical situation. Furthermore, little...

  • Identification of Immunogenic Cytotoxic T Lymphocyte Epitopes Containing Drug Resistance Mutations in Antiretroviral Treatment-Naïve HIV-Infected Individuals. Blanco-Heredia, Juan; Lecanda, Aarón; Valenzuela-Ponce, Humberto; Brander, Christian; Ávila-Ríos, Santiago; Reyes-Terán, Gustavo // PLoS ONE;1/25/2016, Vol. 11 Issue 1, p1 

    Background: Therapeutic HIV vaccines may prove helpful to intensify antiretroviral treatment (ART) efficacy and may be an integral part of future cure strategies. Methods: We examined IFN-gamma ELISpot responses to a panel of 218 HIV clade B consensus-based HIV protease-reverse transcriptase...

  • Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression Snedecor, Sonya J. // Bulletin of Mathematical Biology;Nov2005, Vol. 67 Issue 6, p1315 

    Abstract: Recent advances in the chemotherapy of HIV infection have been successful in delaying the progression of disease in many patients and are responsible for the decline in HIV-related deaths in the United States. Yet, there are many patients who fail to maintain suppressed viral loads on...


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics